Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine
- PMID: 1700230
- DOI: 10.1016/0145-2126(90)90067-j
Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine
Abstract
5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown by an increase in nitroblue tetrazolium reduction, loss of clonogenicity and decrease in DNA synthesis. The concentration of 5-AZA-CdR that produced these effects was in the range of 0.1-1.0 microM. The increase in cytidine deaminase activity became apparent starting at 48 h from the start of the 5-AZA-CdR treatment and at 72 h was about 6-fold greater than the non-treated cell. Since cytidine deaminase is the major enzyme involved in the catabolism of cytosine nucleoside analogues, these results may be relevant in the evaluation of the clinical response of leukemic patients treated with 5-AZA-CdR.
Similar articles
-
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells.Anticancer Drugs. 1992 Jun;3(3):281-7. doi: 10.1097/00001813-199206000-00012. Anticancer Drugs. 1992. PMID: 1381972
-
Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.Leukemia. 1993 May;7 Suppl 1:17-20. Leukemia. 1993. PMID: 7683351
-
Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells.Anticancer Drugs. 1994 Apr;5(2):223-8. doi: 10.1097/00001813-199404000-00014. Anticancer Drugs. 1994. PMID: 7519483
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Feb;11(2):175-80. doi: 10.1038/sj.leu.2400550. Leukemia. 1997. PMID: 9009076 Review.
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Mar;11 Suppl 1:S1-6. Leukemia. 1997. PMID: 9130684 Review.
Cited by
-
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.Cancer Chemother Pharmacol. 1992;30(1):7-11. doi: 10.1007/BF00686478. Cancer Chemother Pharmacol. 1992. PMID: 1375134
-
A rearrangement of the CDD gene at the 5' UTR produces two types of transcripts that contain a natural antisense region.Mol Biol Rep. 1998 Nov;25(4):205-10. doi: 10.1023/a:1006862506479. Mol Biol Rep. 1998. PMID: 9870609
-
miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis.J Cancer Res Clin Oncol. 2012 Apr;138(4):595-602. doi: 10.1007/s00432-011-1137-3. Epub 2012 Jan 1. J Cancer Res Clin Oncol. 2012. PMID: 22209977 Free PMC article.
-
Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.Protein Eng Des Sel. 2016 Dec;29(12):573-582. doi: 10.1093/protein/gzw012. Epub 2016 May 8. Protein Eng Des Sel. 2016. PMID: 27160178 Free PMC article.
-
2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.Br J Cancer. 1993 Feb;67(2):209-15. doi: 10.1038/bjc.1993.41. Br J Cancer. 1993. PMID: 7679279 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources